Health Canada has recently introduced updated guidelines that directly impact micro and standard processing license holders within the cannabis industry.
These guidelines revolve around products intentionally formulated with intoxicating cannabinoids beyond delta-9-THC. Health Canada strongly advocates for these processors to implement identical regulatory measures currently enforced for delta-9-THC across all other intoxicating cannabinoids present in their products.
This unified approach is geared towards maintaining uniformity and, most importantly, accentuating the safety and quality benchmarks for these burgeoning cannabis-based commodities.
- Same rules for all intoxicating cannabinoids: All cannabis products containing intoxicating cannabinoids other than delta-9-THC must follow the same regulations as delta-9-THC products. This includes limits on total intoxicating cannabinoids per container, testing requirements, and clear labelling.
- Focus on safety and quality: These regulations are in place to ensure the safety and quality of these emerging products.
Understanding Intoxicating Cannabinoids:
- What they are: Cannabinoids that interact with the CB1 receptor in the brain, influencing mood, perception, and cognitive function.
- Examples: Delta-8-THC, delta-10-THC, delta-6a-10a-THC, THC-O-acetate (THC-O), CBN, HHC, THCV, THCP, THCB.
Latest Updates on Cannabinoids in Canada:
- New cannabinoids gaining traction: Delta-8-THC, CBN, and HHC are becoming popular alongside delta-9-THC.
- Regulations evolving: Health Canada has established specific guidelines for cannabis licence holders regarding these new cannabinoids.
Recommendations for Licensed Processors:
- Apply the same controls as for delta-9-THC: This includes limits, testing, and labelling requirements.
- Use validated methods for testing: Ensure accurate measurement of all intoxicating cannabinoids.
- Clearly label all intoxicating cannabinoids: Include name, quantity, and the standardized cannabis symbol (THC).
- Labelling: Accurate information on all cannabinoids (names, quantities, THC symbol).
- Reporting: Serious adverse reactions must be reported to Health Canada.
- Packaging: Specific requirements ensure product integrity and consumer safety.
- Record keeping: Maintain detailed records of production and product information.
- Prevention plan: Implement a plan outlining potential hazards and control measures.
- Testing: Regular testing for microbial and chemical contaminants using validated methods.
Adverse Reaction Reporting:
- Report serious adverse reactions to Health Canada within 15 days.
- Submit annual summary reports of all adverse reactions.
- Collect as much information as possible: Details about all cannabinoids present in the product.
- Apply the same regulations as for delta-9-THC to all intoxicating cannabinoids.
- Prioritize safety and quality: Comply with regulations to ensure consumer protection.
- Seek legal consultation to run a smooth business.
- Health Canada may take enforcement measures for non-compliance.
Your Next Step
As a licensed producer, you could be impacted by the latest Health Canada guidance. For further details or to guarantee legal compliance and mitigate business risks, we encourage you to connect with a Cannabis licensing expert today. Please complete the form below to schedule your complimentary consultation session.